Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide


GELINCIK H., KÜPELİ S.

CUKUROVA MEDICAL JOURNAL, vol.41, no.4, pp.811-814, 2016 (Journal Indexed in ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.17826/cutf.254553
  • Title of Journal : CUKUROVA MEDICAL JOURNAL
  • Page Numbers: pp.811-814

Abstract

Ewing sarcoma family of tumor is the second most common bone tumor in children and young adults, after osteosarcoma. Different chemotherapeutic regimens are used in treatment of relapsed/recurrent Ewing sarcoma. Promising results were achieved with combination of irinotecan and temozolomide. Our case was a 13-year-old female with relapsed Ewing sarcoma and after 12 cycles of irinotecan (20 mg/m2/10 days) and temozolomide (100mg/m2/5 days) treatment she had not any complaints, and her radiological lesions remained stable for 66 months. Irinotecan and temozolomide have been used successfully in treatment of relapsed/recurrent Ewing sarcoma, but there is a need for randomized prospective studies with larger patient groups for establishing the efficacy of this treatment protocol.